Knihobot

Modern Strategy for Preclinical Pharmaceutical R&D

Towards the Virtual Research Company

Více o knize

The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.

Nákup knihy

Modern Strategy for Preclinical Pharmaceutical R&D, David Cavalla, John Flack, Richard Jennings

Jazyk
Rok vydání
1997
product-detail.submit-box.info.binding
(pevná)
Jakmile se objeví, pošleme e-mail.

Doručení

Platební metody

Nikdo zatím neohodnotil.Ohodnotit

Titul
Modern Strategy for Preclinical Pharmaceutical R&D
Podtitul
Towards the Virtual Research Company
Jazyk
anglicky
Vydavatel
Wiley
Rok vydání
1997
Vazba
pevná
Počet stran
228
ISBN10
0471971170
ISBN13
9780471971177
Série
Anotace
The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.